Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters

Launched by BOEHRINGER INGELHEIM · Feb 13, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two criteria:
• • 1. Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) \> 140 mmHg but \< 180 mmHg, and/or diastolic BP \> 90 mmHg but \< 110 mmHg).
• • 2. Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.
• Exclusion Criteria:
• • 1. Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
• • 2. Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
• • 3. Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.